Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan A Burger

Showing results (61-70 of 223) with videos related to

Pageof 23
Sort By:
Clinical Advances in Hematology & Oncology : H&O|May 12, 2016
Discussion: Managing Risk When Using IdelalisibSteven E Coutre, Jan A Burger, John M Pagel
Leukemia|December 18, 2018
The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemiaElisa Ten Hacken, Maria Gounari, Paolo Ghia, et al.
Leukemia & Lymphoma|July 3, 2020
Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infectionClaudio Galvao de Castro, Lauro Jose Gregianin, Jan A Burger
Expert Review of Anticancer Therapy|April 21, 2011
Potential of CXCR4 antagonists for the treatment of metastatic lung cancerJan A Burger, David J Stewart, Ori Wald, et al.
Leukemia & Lymphoma|October 13, 2015
CCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltratesElena M Hartmann, Martina Rudelius, Jan A Burger, et al.
Blood|July 29, 2009
The microenvironment in mature B-cell malignancies: a target for new treatment strategiesJan A Burger, Paolo Ghia, Andreas Rosenwald, et al.
Blood|October 7, 2008
AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistanceKumudha Balakrishnan, Jan A Burger, William G Wierda, et al.
Expert Review of Hematology|November 13, 2014
Ibrutinib: a paradigm shift in management of CLLTalha Badar, Jan A Burger, William G Wierda, et al.
Blood|August 5, 2006
CXCR4 is a prognostic marker in acute myelogenous leukemiaAnke C Spoo, Michael Lübbert, William G Wierda, et al.
Blood Research|July 3, 2018
Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) and all-trans retinoic acid (ATRA)Preetesh Jain, Sergej Konoplev, Ohad Benjamini, et al.
Pageof 23

Showing results (61-70 of 223) with videos related to

Sort By:
Pageof 23
Clinical Advances in Hematology & Oncology : H&O|May 12, 2016
Discussion: Managing Risk When Using IdelalisibSteven E Coutre, Jan A Burger, John M Pagel
Leukemia|December 18, 2018
The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemiaElisa Ten Hacken, Maria Gounari, Paolo Ghia, et al.
Leukemia & Lymphoma|July 3, 2020
Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infectionClaudio Galvao de Castro, Lauro Jose Gregianin, Jan A Burger
Expert Review of Anticancer Therapy|April 21, 2011
Potential of CXCR4 antagonists for the treatment of metastatic lung cancerJan A Burger, David J Stewart, Ori Wald, et al.
Leukemia & Lymphoma|October 13, 2015
CCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltratesElena M Hartmann, Martina Rudelius, Jan A Burger, et al.
Blood|July 29, 2009
The microenvironment in mature B-cell malignancies: a target for new treatment strategiesJan A Burger, Paolo Ghia, Andreas Rosenwald, et al.
Blood|October 7, 2008
AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistanceKumudha Balakrishnan, Jan A Burger, William G Wierda, et al.
Expert Review of Hematology|November 13, 2014
Ibrutinib: a paradigm shift in management of CLLTalha Badar, Jan A Burger, William G Wierda, et al.
Blood|August 5, 2006
CXCR4 is a prognostic marker in acute myelogenous leukemiaAnke C Spoo, Michael Lübbert, William G Wierda, et al.
Blood Research|July 3, 2018
Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) and all-trans retinoic acid (ATRA)Preetesh Jain, Sergej Konoplev, Ohad Benjamini, et al.
Pageof 23